诺思格(301333) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥177,331,193.71, representing a 10.19% increase compared to ¥160,932,583.88 in the same period last year[5] - Net profit attributable to shareholders decreased by 19.95% to ¥23,048,890.81 from ¥28,792,801.97 year-on-year[5] - The company's basic earnings per share decreased by 20.00% to ¥0.24 from ¥0.30 in the same period last year[5] - Net profit for Q1 2024 was ¥23,572,914.21, a decrease of 17.6% from ¥28,678,469.89 in Q1 2023[26] - Total comprehensive income for the first quarter was CNY 23,547,386.22, a decrease from CNY 28,776,416.25 in the previous year[27] Cash Flow - The net cash flow from operating activities increased by 30.95% to ¥23,298,356.28, up from ¥17,791,127.98 in the previous year[15] - Cash inflow from operating activities totaled CNY 174,489,133.55, compared to CNY 159,186,923.75 in the previous year, reflecting a growth of 9.2%[30] - Cash outflow from operating activities was CNY 151,190,777.27, up from CNY 141,395,795.77, indicating a rise of 6.0%[30] - The company’s net cash flow from financing activities was negative CNY 9,253,748.32, worsening from negative CNY 2,884,230.04 in the previous year[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,207,965,570.12, a 6.47% increase from ¥2,073,816,068.79 at the end of the previous year[5] - The total liabilities increased to ¥431,176,262.56 from ¥319,165,864.52, reflecting a rise of 35.0%[24] - The equity attributable to shareholders rose to ¥1,774,302,419.69 from ¥1,748,411,556.50, an increase of 1.5%[24] Expenses - Management expenses rose by 77.97% to ¥27,734,313.59, primarily due to increased share-based payment amounts related to the equity incentive policy[12] - Operating costs for Q1 2024 were ¥155,064,411.27, up from ¥135,498,900.38 in the same period last year, reflecting a rise of 14.5%[25] - Research and development expenses increased to ¥14,126,228.84, compared to ¥13,570,366.43 in the previous year, marking a rise of 4.1%[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 6,943[16] - ACE UNION HOLDING LIMITED holds 28.68% of shares, totaling 27,532,800 shares[16] - Ningbo Kaihong Venture Capital Partnership holds 12.23% of shares, totaling 11,736,000 shares[16] - Ningbo Kangyunfu Equity Investment Co., Ltd. holds 12.00% of shares, totaling 11,520,000 shares[16] - The total number of shares held by the top ten unrestricted shareholders is 40,000,000 shares[17] - The top ten shareholders do not participate in margin financing and securities lending[18] - The company’s stock ownership structure includes significant holdings by domestic private entities[16] Acquisitions and Investments - The company acquired 100% equity of Shanghai Hengling Pharmaceutical Technology Co., Ltd. in January 2024[20] - The company plans to jointly invest in an industrial fund with China International Capital Corporation[21] - The company has established a new subsidiary, increasing its investment capabilities[21] Other Financial Metrics - The company reported a significant increase in goodwill by 102,005.36% to ¥85,601,229.63 due to the acquisition of subsidiaries[10] - The weighted average return on net assets decreased to 1.31% from 1.80% year-on-year[5] - The company reported a 464.20% increase in fair value changes in profit to ¥2,881,691.79, attributed to an increase in bank wealth management products and structured deposits[12] - The company reported a decrease in other comprehensive income, with a net loss of ¥25,527.99 compared to a gain of ¥97,946.36 in the previous year[26] - Cash and cash equivalents decreased to ¥811,083,363.11 from ¥991,479,479.20, a decline of 18.2%[23] - Accounts receivable increased to ¥108,114,856.07 from ¥89,996,806.71, representing a growth of 20.1%[23]